Table 1.
Baseline characteristics of advanced NSCLC patients with EGFR mutations
| Character | N (%) |
|---|---|
| Age, year | |
| Median (range) | 53 (31–83) |
| Gender | |
| Female | 19 (61.3%) |
| Male | 12 (38.7%) |
| ECOG PS | |
| 0 | 4 (12.9%) |
| 1 | 17 (54.8%) |
| 2 | 10 (32.3%) |
| Smoking status | |
| Never | 23 (74.2%) |
| Ever | 8 (25.8%) |
| Pathology | |
| Adenocarcinoma | 31 (100%) |
| Tumor stage | |
| IVA | 5 (16.1%) |
| IVB | 3 (9.7%) |
| IVC | 23 (74.2%) |
| Metastatic sites | |
| Number (median, range) | 3 (1–5) |
| Lymph nodes | 18 (58.1%) |
| Brain | 18 (41.9%) |
| Lung | 17 (54.8%) |
| Bone | 16 (51.6%) |
| Liver | 7 (22.6%) |
| Pleura | 11 (35.5%) |
| Adrenal glands | 4 (12.9%) |
| EGFR gene mutation | |
| EGFR 19del | 16 (51.6%) |
| EGFR 21L858R | 12 (38.7%) |
| Other | 3 (9.7%) |
| EGFR T790M status | |
| Positive | 11 (35.5%) |
| Negative | 15 (48.4%) |
| Not detected | 5 (16.1%) |
| PD‐L1 status | |
| ≥50% | 5 (16.1%) |
| 1–50% | 2 (6.5%) |
| Negative/unknown | 24 (77.4%) |